Hearing Nothing Doesn't Mean Nothing's Happening
Are your patients still on BPH meds?
They may be silently suffering. Intervening earlier with treatments that address the blockage may preserve bladder health.6 Partner with UroLift-trained urologists in your area to support a faster care pathway.
Are you frustrated by medication nonadherence and the challenges of polypharmacy?
About half of men surveyed are dissatisfied with their BPH medication.3
Up to 71% of patients are non-adherent with their BPH meds after one year.4
Of men on BPH medications experience <4 point IPSS symptom improvement5
Help Your Patients Preserve Bladder Health
Impact on wellbeing
Quality of life and overall health are important considerations in treating men with BPH. Watchful waiting can risk long-term bladder health.6 The use of BPH medications may be associated with potential side effects,7 and many men are dissatisfied with the effectiveness of their BPH medication in relieving symptoms.3,5

“Since many men discontinue medical therapy, yet proportionately few seek surgery, there is a large clinical need for an effective treatment that is less invasive than surgery.”
The UroLift™ System Advantage
A mechanical solution to a mechanical problem
The UroLift™ System uses a proven approach to treating BPH that lifts and holds the enlarged prostate tissue out of the way, so it no longer blocks the urethra. It is the leading transurethral BPH treatment that does not require heating, cutting or removal of the prostate tissue.13,14 Post-procedure, most patients do not require ongoing BPH medications.15
Refer your appropriate patients to a urologist who can determine if they are a candidate for the UroLift™ System.
The system procedure is a proven minimally invasive technology designed to treat men with an enlarged prostate caused by benign prostatic hyperplasia or BPH. It has been shown to relieve urinary symptoms and improve quality of life with minimal side effects. The system treatment is often performed in a clinic setting under local anesthesia. The is the current generation of the UroLift system. It consists of a delivery handle and individual implant cartridges containing a single implant used for each implant placement. This cartridge based system enables a streamlined procedure while also significantly reducing packaging waste. The actual UroLift implant remains unchanged to sustain proven outcomes building on years of clinical research and real world successes. The UroLift System procedure begins by inserting an implant delivery device into the urethra. An inserted cystoscope provides the physician with visibility to the anatomy. Once the tip of the delivery device is in the bladder, the needle safety is pressed to unlock the device. On reaching the area of the urethra blocked by the enlarged prostate, the obstructive tissue is moved aside. A trigger pull inserts a curved nineteen gauge nitinol needle through the prostate. A second trigger pull deploys the implant, anchoring a small nitinol tab outside of the prostate while partially retracting the needle. Attached to the nitinol tab is a length of monofilament PET suture. A third trigger pull fully retracts the needle and tensions the suture. Trigger pull number four completes the implant by placing a stainless steel urethral end piece onto the suture while also cutting the suture. Depending on the prostate size and amount of blockage, additional implants may be placed in the same way. The physician will determine the number of implants needed per each individual patient to obtain an open anterior channel. The outer capsule of the prostate is firm and provides a solid anchor. This allows the implants to lift and hold the enlarged prostate tissue out of the way so it no longer blocks the urethra. The implant size is customized to each individual patient and prostate lobe. As the suture is tensioned, it also shortens, compressing the prostate lobes to the side. This reduces pressure on the urethra and provides immediate visible results so urine can flow freely. It's a mechanical solution to a mechanical problem. The minimally invasive procedure requires no cutting, heating, or tissue removal. This procedure preserves sexual function. It typically also means minimal downtime, mild to moderate side effects, and a quick return to normal activity. The system provides a clinically proven treatment for men who suffer from an enlarged prostate that may help get men off BPH medications and may help avoid major surgery.
The UroLift™ System reopens the channel—with no cutting or burning of the prostate.
Common Questions Your Patients May Ask
What’s the harm in watchful waiting?
87% of men who elect watchful waiting reported a worsening of symptoms over a 4-year period.9
Can I continue taking my BPH medications forever?
Some BPH medications have been associated with serious issues, such as increased risk of cardiac failure and impaired cognitive function.1,2,10
What about sexual function?
UroLift™ System patients reported better outcomes in sexual function* and satisfaction than men who received BPH medication.12
Connect with a Teleflex representative to learn more and get resources for your staff and patients.
Download an IPSS form to help identify patients who may benefit from the UroLift™ System treatment.
Review the Clinical Data
Data from 145 peer-reviewed and 22 sponsored publications about the UroLift™ System.
Learn MoreGet Patient Perspectives
Watch videos and read blogs about real-life experience with the UroLift System.
Learn MoreBPH Advisor
Patients can take a short quiz to get a personalized, detailed BPH report and receive helpful articles by text or email.
Learn MoreReferences
1. Duan, Pharmacoepidemiol Drug Saf 2018
2. Welk, J Neurol Sci 2017
3. Survey of US men aged 40+ who have been diagnosed with BPH (enlarged prostate) and are/have been treated with BPH medications, conducted by Teleflex in 2020. Data on file, n=96.
4. Cindolo, Eur Urol 2015
5. Wei, et al, 2010 Abstract
6. Flanigan, J Urol 1998
7. AUA Guidelines 2003
8. Tubaro, Drugs Aging 2003
9. Djavan, Urology 2004
10. Lusty, J Urol 2021
12. Roehrborn, Eur Urol Focus 2021
13. Roehrborn, J Urol 2013
14. AUA Guidelines 2003, 2020
15. Roehrborn, Can J Urol 2017
*Based on an indirect comparison of erectile and ejaculatory function and sexual satisfaction in men who received PUL in controlled studies or in men who received medical therapy in the MTOPS study.
+ Dr. Robert Cowles was previously a paid consultant of Teleflex
MAC03180-01 Rev A